EN DE
Watch 3billion for free: we tell you when fair value or trend changes.
Data-driven stock valuation

3billion (394800) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of 3billion stock KRW 4,282, price KRW 6,440, that is 33.5% below the price, quality 53 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

3 3billion logo Thin data Nov 10, 2026

3billion

394800 · KQ
Expensive, in a downtrend

Our calculation puts a fair price 34% below what the stock costs today.

Revenue last quarter +103% vs. a year ago.
Quality 53/100
Expensive Growth (revenue 3y +141.8 %/yr in KRW)
Fair value 4,282 KRW · Overvalued
Loss-making · -61.0% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch 3billion for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

18,800 KRW 3,080 KRW Fair Value 4,282 KRW Nov 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

24‑month range 3,080 KRW – 18,800 KRW · fair‑value band 3,212 KRW – 5,353 KRW · the 6,440 KRW price screens above the 4,282 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow 3billion in your weekly email

Every Wednesday you see whether 3billion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment.

Show moreShow less

It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as well as provides various affiliated services to customers. The company was founded in 2016 and is based in Seoul, South Korea.

Stock analysis

3billion (394800) currently trades at 6,440 KRW, while our estimate is 4,282 KRW, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 3,212 KRW (bear) to 5,353 KRW (bull), the price of 6,440 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

3billion reported revenue of 11.7B KRW in FY2025 versus 551M KRW in FY2021, a compound +114.7%/yr. Reported net income was −5.4B KRW in FY2025.

Key figures

Market cap 204B KRW (≈ $153M) Micro · P/S ratio 17.9 · EPS (TTM) −187.51 KRW · Net margin −61.0% · Return on equity −29.2% · Return on assets (EBIT) −28.6% (5-year average) · Operating margin −39.3% · Revenue (TTM) 9.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 59% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, 394800 screens richer than that median.

Fair Value

Bear 3,212 KRW Fair Value 4,282 KRW Bull 5,353 KRW
Price 6,440 KRW · Downside -33.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19
How much profit the company makes from its sales and capital
Quality Growth 97
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 42
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+102.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+141.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,216.4% (2021) → −50.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

394800 screens overvalued: fair value 34% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare 3billion with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Top 25%
Fair Value upside −33.5% · Below median
Profitability
Return on assets −18.2% · Above median
Net margin (12 months) −61.0% · Below median
Operating margin (12 months) −39.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 102.5% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.66× · Priciest 25%
P/S (12 months) 20.88× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 394800
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 394800
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 394800
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 394800
argenx SE ARGX $971.55 $908.40 −7% vs 394800
CSL Limited CSL A$201.68 A$181.40 −10% vs 394800
Moderna, Inc MRNA $250.83 $158.70 −37% vs 394800
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 394800
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 394800
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 394800

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

3billion: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "3billion Fair Value". https://www.fairvalue-calculator.com/stock/394800

Frequently asked questions

Is 3billion (394800) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 4,282 KRW versus a price of 6,440 KRW, about 34% lower (overvalued).
What is the fair value of 394800?
Our estimate for 3billion is 4,282 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 6,440 KRW.
What is the quality score of 394800?
3billion has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 3billion (394800)?
Our calculated price target is the estimate of 4,282 KRW (as of Nov 10, 2026). Cautious scenario 3,212 KRW, optimistic scenario 5,353 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the 3billion stock forecast for 2026?
Our estimate puts fair value at 4,282 KRW, about 34% lower versus a price of 6,440 KRW (overvalued). Cautious scenario 3,212 KRW, optimistic scenario 5,353 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of 3billion (394800)?
3billion reported trailing-twelve-month revenue of about 9.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of 3billion (394800)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 3billion it is 4,282 KRW per share (as of Nov 10, 2026), against a price of 6,440 KRW.
Is 3billion stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 394800 trades above its calculated fair value: price 6,440 KRW, fair value 4,282 KRW, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 394800?
No. The price is what the market pays today (6,440 KRW); the fair value is what the company's own numbers justify (4,282 KRW). For 3billion the two are 2,158 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is 3billion worth?
The market values 3billion at about 204B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 6,440 KRW; our models calculate a fair value of 4,282 KRW per share.
What do the bullish and bearish scenarios say about 394800?
Our models span a range for 3billion: cautious scenario 3,212 KRW, base 4,282 KRW, optimistic 5,353 KRW per share (as of Nov 10, 2026, price 6,440 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 3billion (394800)?
Balance-sheet figures for 3billion (as of Nov 10, 2026): return on equity −29.2%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 394800 from its 52-week high?
3billion trades at 6,440 KRW, about 66% below its 52-week high of 18,800 KRW and 59% above the low of 4,060 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 4,282 KRW is for.
Which stocks are comparable to 3billion?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 3billion stock attractive at the current price?
The data as of Nov 10, 2026: price 6,440 KRW, calculated fair value 4,282 KRW (−34%), Quality Score 53/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. 3billion itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 3billion (394800)?
The closing price on Nov 10, 2026 was 6,440 KRW. Our estimate is 4,282 KRW, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 3billion right now?
The price sits above even our optimistic bull case (5,353 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of 3billion

How large is the market capitalisation of 3billion (394800)?
The market capitalisation of 3billion is 204B KRW (≈ $153M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 3billion (394800)?
The price-to-sales ratio of 3billion is 17.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 3billion (394800)?
Earnings per share at 3billion are −187.51 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of 3billion (394800)?
The net margin of 3billion is −61.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of 3billion (394800)?
The return on equity (ROE) of 3billion is −29.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 3billion (394800)?
On an EBIT basis the return on assets of 3billion is −28.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 3billion (394800)?
The operating margin of 3billion is −39.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 3billion (394800)?
Revenue at 3billion is growing +103% versus a year earlier (3y avg +142%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 3billion (394800) generate?
The free cash flow of 3billion is −5.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch 3billion in the live analysis

One click puts 3billion on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.